AT500282A3 - Neurotrophe und neuroprotektive peptide - Google Patents

Neurotrophe und neuroprotektive peptide Download PDF

Info

Publication number
AT500282A3
AT500282A3 AT0049502A AT4952002A AT500282A3 AT 500282 A3 AT500282 A3 AT 500282A3 AT 0049502 A AT0049502 A AT 0049502A AT 4952002 A AT4952002 A AT 4952002A AT 500282 A3 AT500282 A3 AT 500282A3
Authority
AT
Austria
Prior art keywords
neurotrophic
neuroprotective peptides
neuroprotective
peptides
Prior art date
Application number
AT0049502A
Other languages
English (en)
Other versions
AT500282A2 (de
Inventor
Manfred Dr Windisch
Original Assignee
Jsw Res Forschungslabor Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jsw Res Forschungslabor Gmbh filed Critical Jsw Res Forschungslabor Gmbh
Priority to AT0049502A priority Critical patent/AT500282A3/de
Priority to PCT/AT2003/000065 priority patent/WO2003082906A2/de
Priority to CA002480633A priority patent/CA2480633A1/en
Priority to NZ535623A priority patent/NZ535623A/en
Priority to EP03707885A priority patent/EP1499636A2/de
Priority to AU2003212074A priority patent/AU2003212074A1/en
Priority to US10/509,095 priority patent/US20060036073A1/en
Priority to JP2003580370A priority patent/JP2006508022A/ja
Publication of AT500282A2 publication Critical patent/AT500282A2/de
Publication of AT500282A3 publication Critical patent/AT500282A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT0049502A 2002-03-28 2002-03-28 Neurotrophe und neuroprotektive peptide AT500282A3 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AT0049502A AT500282A3 (de) 2002-03-28 2002-03-28 Neurotrophe und neuroprotektive peptide
PCT/AT2003/000065 WO2003082906A2 (de) 2002-03-28 2003-03-10 Neurotrophe und neuroprotektive peptide
CA002480633A CA2480633A1 (en) 2002-03-28 2003-03-10 Neurotrophic and neuroprotective peptides
NZ535623A NZ535623A (en) 2002-03-28 2003-03-10 Peptides, 4-14 amino acids in length, for treating degenerative conditions of the CNS
EP03707885A EP1499636A2 (de) 2002-03-28 2003-03-10 Neurotrophe und neuroprotektive peptide
AU2003212074A AU2003212074A1 (en) 2002-03-28 2003-03-10 Neurotrophic and neuroprotective peptides
US10/509,095 US20060036073A1 (en) 2002-03-28 2003-03-10 Neurotrophic and neuroprotective peptides
JP2003580370A JP2006508022A (ja) 2002-03-28 2003-03-10 神経栄養性および神経保護性ペプチド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0049502A AT500282A3 (de) 2002-03-28 2002-03-28 Neurotrophe und neuroprotektive peptide

Publications (2)

Publication Number Publication Date
AT500282A2 AT500282A2 (de) 2005-11-15
AT500282A3 true AT500282A3 (de) 2006-06-15

Family

ID=28458152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0049502A AT500282A3 (de) 2002-03-28 2002-03-28 Neurotrophe und neuroprotektive peptide

Country Status (8)

Country Link
US (1) US20060036073A1 (de)
EP (1) EP1499636A2 (de)
JP (1) JP2006508022A (de)
AT (1) AT500282A3 (de)
AU (1) AU2003212074A1 (de)
CA (1) CA2480633A1 (de)
NZ (1) NZ535623A (de)
WO (1) WO2003082906A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2383123T3 (es) * 2004-06-29 2012-06-18 Aventis Pharmaceuticals Inc. Composición de unión a FKBP y su uso farmacéutico
JP5190957B2 (ja) * 2006-04-28 2013-04-24 国立大学法人 鹿児島大学 アミロイドβ線維化阻害ペプチド
AT504553B1 (de) * 2006-12-06 2008-09-15 Jsw Res Forschungslabor Gmbh Peptidomimetika aus rechtsdrehenden aminosäuren sowie diese enthaltende arzneimittel zur behandlung von neurodegenerativen erkrankungen
EP2406279B1 (de) 2009-03-09 2016-01-27 Ramot at Tel-Aviv University Ltd. Zusammensetzungen zur prävention und behandlung von neurodegenerativen erkrankungen
JP5664992B2 (ja) * 2009-08-26 2015-02-04 国立大学法人名古屋大学 細胞特異的ペプチド及びその用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060794A2 (en) * 2000-02-18 2001-08-23 The Regents Of The University Of California Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1257806A (en) * 1984-11-19 1989-07-25 Siamak A. Adibi Nutrient compositions
JP2002538076A (ja) * 1998-10-06 2002-11-12 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 抗アミロイド発生特性をスクリーニングする方法および神経変性疾病を治療する方法
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
WO2002004482A1 (en) * 2000-07-07 2002-01-17 Panacea Pharmaceuticals, Inc. Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060794A2 (en) * 2000-02-18 2001-08-23 The Regents Of The University Of California Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hashimoto M. et al:"Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro." Neuroreport. 1999 March 17;10(4):717-21. *Ganzes Dokument* *
Ostrerova-Golts N. et al:"The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity." J. Neurosci., 2000 Aug 15;20(16):6048-54. *Ganzes Dokument* *
Paxinou E. et al:"Induction of alpha-synuclein aggregation by intracellular nitrative insult.", J. Neurosci. 2001 Oct. 15;21(20):8053-61 *Ganzes Dokument* *

Also Published As

Publication number Publication date
WO2003082906A2 (de) 2003-10-09
US20060036073A1 (en) 2006-02-16
AU2003212074A1 (en) 2003-10-13
JP2006508022A (ja) 2006-03-09
AT500282A2 (de) 2005-11-15
NZ535623A (en) 2007-03-30
EP1499636A2 (de) 2005-01-26
WO2003082906A3 (de) 2004-11-25
CA2480633A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
EP1402001A4 (de) Antimikrobielle peptide und zusammensetzungen
DK1680443T3 (da) Stabiliserede alfa-helix-peptider og anvendelser heraf
HUP0500992A3 (en) Tacis and br3 polypeptides and uses thereof
EP1441750A4 (de) Lineare und cyclische melanocortin-rezeptor-spezifische peptide
EP1732581A4 (de) Polypeptidtransduktion und fusogene peptide
EP1461605A4 (de) Protein- und peptid-nanoarrays
IL199528A0 (en) Recombinant lubricin molecules and uses thereof
DE60327407D1 (de) Immunmodulierende peptide
EP1414848A4 (de) Replikin-peptide und ihre verwendungszwecke
EP1462455A4 (de) Neue peptide und deren medizinische verwendungen
EP1419175A4 (de) Replikin-peptide und anwendungen
DE60334194D1 (de) Transmembranes nfat-hemmendes peptid
AT500282A3 (de) Neurotrophe und neuroprotektive peptide
EP1565553A4 (de) Rekombinante katalytische polypeptide und deren verwendungen
GB0309064D0 (en) Modified peptides and their uses
AU2003290886A8 (en) Modified alpha-msh peptides and derivatives thereof
NO20032963L (no) Peptidforbindelser
EP1389126A4 (de) Retrocycline: antivirale und antimikrobielle peptide
EP1411964A4 (de) Die blutgerinnung modulierende peptide und ihre verwendungszwecke
EP1337543A4 (de) Streptavidin-bindende peptide und deren verwendung
EP1487459A4 (de) Peptid-analoga und ihre verwendung
FI20040655A0 (fi) Proteiini- ja peptidistabilointi
EP1699809A4 (de) Amniotisches peptid und anwendungen davon
NO20050436D0 (no) Beta-lagnedbrytende peptider
IL149179A0 (en) FcyRII-BINDING PEPTIDES AND USES THEREOF

Legal Events

Date Code Title Description
REJ Rejection

Effective date: 20160515